Global Seasonal Influenza Therapeutics Sales Market Professional Survey Report 2017

Seasonal Influenza Therapeutics Market in Asia-Pacific industry to 2022 - Growth Driven by Rising Elderly Population, Growing Awareness and Launch of Quadrivalent Therapies

Influenza, often referred to as the flu, is an acute infection caused by one of the three closely related viruses, designated as influenza Type A, B, and C. The infection’s rapid onset and potential for high morbidity and mortality, particularly in high-risk patient populations such as the elderly and young children, make prompt and effective treatment with antiviral medication very difficult. For these reasons, prophylactic vaccination is the preferred intervention for seasonal influenza.

Request a sample copy @ https://marketsizeforecasters.com/get-sample/2762

In the recent years it was observed that demand for seasonal influenza vaccines have increased due to changed perception of patient population. APAC region is an attractive market for seasonal influenza vaccine manufacturers. Continuous improvements in the formulation of vaccines has occurred over the years, with the market currently transitioning from trivalent to quadrivalent formulations, which offer protection against an additional B strain of the virus. Traditional egg based manufacturing of seasonal influenza vaccines is being replaced with cell culture vaccines. Cell culture based production of vaccines is expected to reduce the problems associated with the production and use of seasonal influenza vaccines which will further increase the vaccination coverage in the APAC region.

Global Seasonal Influenza Therapeutics Market of 108 pages having tables and figures is available for purchase at https://marketsizeforecasters.com/securecheckout/paymenta/2762?msfpaycode=sumsf

GBI Research’s analysis shows that the R&D pipeline for seasonal influenza vaccines comprises a high number of vaccines in early-stage development, many of which are new formulations or those that have been developed using the cell culture method. Late-stage vaccines are either quadrivalent vaccines or pediatric versions of those that have already been approved. GBI Research expects that quadrivalent seasonal influenza vaccines will replace their trivalent vaccines forerunner by the end of the forecast period.

Browse full table of contents and data tables @ https://marketsizeforecasters.com/seasonal-influenza-therapeutics-in-asia-pacific-markets

Major Points Covers in Table of Contents

1 Table of Contents
1 Table of Contents 4
1.1 List of Tables 7
1.2 List of Figures 7

2 Introduction 9
2.1 Disease Introduction 10
2.2 Epidemiology 10
2.3 Symptoms 12
2.4 Etiology and Pathophysiology 13

3 Marketed Products 23
3.1 Overview 23
3.2 Fluarix Tetra - GlaxoSmithKline 23
3.3 FluQuadri - Sanofi Pasteur 25

The listed pricing for this Global Seasonal Influenza Therapeutics Market report starts at $ 4995. Request Discount for Global Seasonal Influenza Therapeutics Market Research Report @ https://marketsizeforecasters.com/enquire-for-discount/2762

Related Reports: -

Global Infantile Spasms Therapeutics Market 2017-2021

An infantile spasm is a particular type of seizure found in an epilepsy syndrome of infancy and childhood. It is also known as a West syndrome. The onset of infantile spasm is usually found in the first year of life between four months and eight months of age.

https://marketsizeforecasters.com/global-infantile-spasms-therapeutics-market

Centralize Market Research Purchases Across Your Entire Organization In One Place Marketsizeforecasters.Com Allows You To Manage And Control All Corporate Research Purchases To Consolidate Billing And Vendor Management. You Can Eliminate Duplicate Purchases And Customize Your Content And License Management.

Market Size Forecasters
The Green Suite #4594,
Dover, DE 19901
United States
Phone: 1-201-355-0868
US Toll Free: 1-866-764-2150
Email: Sales@Marketsizeforecasters.Com
Website: Http://Marketsizeforecasters.Com/
Connect With Us: Linkedin | Twitter

This release was published on openPR.